{"id":479713,"date":"2020-04-16T12:52:02","date_gmt":"2020-04-16T12:52:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=479713"},"modified":"2020-04-16T12:52:02","modified_gmt":"2020-04-16T12:52:02","slug":"synovial-sarcoma-ss-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/synovial-sarcoma-ss-epidemiology-forecast-to-2030_479713.html","title":{"rendered":"Synovial sarcoma (SS) &#8211; Epidemiology Forecast to 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1587017159.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Synovial sarcoma (SS) - Epidemiology Forecast to 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1587017159.jpeg\" alt=\"Synovial sarcoma (SS) - Epidemiology Forecast to 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8216;Synovial sarcoma (SS) &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Synovial sarcoma (SS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight<\/strong> launched a new report on&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/synovial-sarcoma-ss-epidemiology-forecast\" target=\"_blank\">Synovial sarcoma (SS) &#8211; Epidemiology Forecast to 2030<\/a>.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216;<strong>Synovial sarcoma (SS) &#8211; Epidemiology Forecast to 2030<\/strong>&#8216; report delivers an in-depth understanding of the disease, historical and forecasted Synovial sarcoma (SS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>The ley facts of the report:<\/strong><br \/>1. The United accounted for most synovial sarcoma incident cases in 7MM with 576 cases in 2017.<br \/>2. Among EU5, Germany has the highest number of synovial sarcoma incident cases accounting for 331cases in 2017.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/9eff5bbc98fec74d64d4d10c5863b702.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report:<br \/><\/strong>1. Synovial Sarcoma market report covers a descriptive overview and comprehensive insight of the Synovial Sarcoma epidemiology and Synovial Sarcoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<br \/>2. Synovial Sarcoma market report provides insights on the current and emerging therapies.<br \/>3. Synovial Sarcoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.<br \/>4. Synovial Sarcoma market report offers an edge that will help in developing business strategies by understanding trends moulding and leading the Synovial Sarcoma market.&nbsp;<\/p>\n<p><strong>Scope of the Report:<br \/><\/strong>1.&nbsp;The Synovial sarcoma (SS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<br \/>2. The Synovial sarcoma (SS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Synovial sarcoma (SS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)<br \/>3. The report provides insight about the historical and forecasted patient pool of Synovial sarcoma (SS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<br \/>4. The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<br \/>5. The report assesses the disease risk and burden and highlights the unmet needs of Synovial sarcoma (SS)<br \/>6. The report provides the segmentation of the Synovial sarcoma (SS) epidemiology<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample pages:<\/strong>&nbsp;https:\/\/www.delveinsight.com\/sample-request\/synovial-sarcoma-ss-epidemiology-forecast<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<br \/><\/strong>1.&nbsp;Key Insights&nbsp;<br \/>2. Executive Summary of Synovial sarcoma (SS)<br \/>3.&nbsp;Synovial sarcoma (SS): Disease Background and Overview<br \/>4.&nbsp;Patient Journey<br \/>5.&nbsp;Epidemiology and Patient Population<br \/>6.&nbsp;Treatment Algorithm, Current Treatment, and Medical Practices<br \/>7.&nbsp;KOL Views<br \/>8.&nbsp;Unmet Needs<br \/>9.&nbsp;&nbsp;Appendix<br \/>10.&nbsp;DelveInsight Capabilities<br \/>11.&nbsp;Disclaimer<br \/>12.&nbsp;About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight:<br \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=synovial-sarcoma-ss-epidemiology-forecast-to-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=synovial-sarcoma-ss-epidemiology-forecast-to-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8216;Synovial sarcoma (SS) &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Synovial sarcoma (SS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/synovial-sarcoma-ss-epidemiology-forecast-to-2030_479713.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-479713","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/479713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=479713"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/479713\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=479713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=479713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=479713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}